Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Clin Colorectal Cancer ; 23(2): 128-134.e1, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38735828

RÉSUMÉ

BACKGROUND: Standard of care for most patients with locally advanced rectal cancer in The Netherlands consists of neoadjuvant chemoradiotherapy (nCRT) followed by resection. Enlarged lateral lymph nodes (LLNs), especially in the iliac compartment, appears to be associated with an increased risk of local recurrence. Little is known about the risk of local recurrence after nCRT. MATERIALS AND METHODS: This study included patients with locally advanced rectal cancer and enlarged LLNs on pretreatment MRI-scan located in the internal iliac, obturator, external iliac, or common iliac compartment. Patients were treated with nCRT and response to therapy was evaluated with MRI-scan. The primary endpoint was local lateral recurrence after nCRT. Secondary endpoints included overall survival and postoperative complications. RESULTS: Out of 260 patients treated for rectal cancer, a total of 46 patients with enlarged LLNs (18% of all patients) were included between 2012 and 2019 in 2 Dutch hospitals. No patients had lateral lymph node recurrence (LLNR) after nCRT. Only 1 patient had local recurrence of rectal cancer after radical resection during a median follow up of 3 years. Disseminated disease was seen in 12 patients and 9 patients died during follow-up, which result in an overall survival rate of 80.4%. Postoperative complications were seen in 41% of patients. There was no 90-days postoperative mortality. CONCLUSION: Enlarged LLNs are rare after nCRT and no LLNR was found after nCRT in our study population. This could suggest that nCRT only with or without an extra radiotherapeutic boost on enlarged LLNs already reduces the risk of LLNR.


Sujet(s)
Noeuds lymphatiques , Métastase lymphatique , Traitement néoadjuvant , Récidive tumorale locale , Tumeurs du rectum , Humains , Tumeurs du rectum/thérapie , Tumeurs du rectum/anatomopathologie , Tumeurs du rectum/mortalité , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Noeuds lymphatiques/anatomopathologie , Traitement néoadjuvant/méthodes , Récidive tumorale locale/prévention et contrôle , Récidive tumorale locale/épidémiologie , Adulte , Pays-Bas/épidémiologie , Taux de survie , Imagerie par résonance magnétique/méthodes , Études rétrospectives , Chimioradiothérapie/méthodes , Études de suivi , Proctectomie , Complications postopératoires/épidémiologie , Complications postopératoires/étiologie , Sujet âgé de 80 ans ou plus , Chimioradiothérapie adjuvante/méthodes , Chimioradiothérapie adjuvante/statistiques et données numériques
2.
Cancers (Basel) ; 13(17)2021 Aug 26.
Article de Anglais | MEDLINE | ID: mdl-34503113

RÉSUMÉ

Thermal ablation and stereotactic ablative radiotherapy (SABR) are techniques to eradicate colorectal liver metastases (CRLM). This study compares the safety, efficacy and long-term oncological outcomes of these treatment methods. All prospectively registered patients (AmCORE registry) treated with thermal ablation or SABR alone for unresectable CRLM between 2007 and 2020 were analyzed using multivariate Cox-proportional hazard regression. In total 199 patients were included for analysis: 144 (400 CRLM) thermal ablation; 55 (69 CRLM) SABR. SABR patients were characterized by older age (p = 0.006), extrahepatic disease at diagnosis (p = 0.004) and larger tumors (p < 0.001). Thermal ablation patients were more likely to have synchronous disease, higher clinical risk scores (p = 0.030) and higher numbers of CRLMs treated (p < 0.001). Mortality was zero and morbidity low in both groups: no serious adverse events were recorded following SABR (n = 0/55) and nine (n = 9/144 [6.3%]; all CTCAE grade 3) after thermal ablation. SABR was associated with an inferior overall survival (OS) (median OS 53.0 months vs. 27.4 months; HR = 1.29, 95% CI 1.12-1.49; p = 0.003), local tumor progression-free survival (LTPFS) per-tumor (HR = 1.24, 95% CI 1.01-1.52; p = 0.044) and local control per-patient (HR = 1.57, 95% CI 1.20-2.04; p = 0.001) and per-tumor (HR = 1.89, 95% CI 1.44-2.49; p < 0.001). In this study thermal ablation was superior to SABR with regard to OS, LTPFS and local control, albeit at the cost of a limited risk of serious adverse events. Further studies are required to assess whether the worse outcomes following SABR were the effect of true differences in ablative treatment or a result of residual confounding.

3.
Pract Radiat Oncol ; 11(6): 502-509, 2021.
Article de Anglais | MEDLINE | ID: mdl-34273596

RÉSUMÉ

PURPOSE: Small, hypoattenuating, indeterminate liver lesions are often encountered during staging computed tomography (CT) in patients with early-stage rectal cancer. This study aimed to determine the incidence and prognostic significance of these lesions. METHODS AND MATERIALS: A single institution's colorectal cancer (CRC) database was searched for patients with early-stage rectal cancer, defined as a cT1-2N0 tumor on magnetic resonance imaging (MRI). Abdominal CT scans of these patients were assessed for the presence of liver lesions and categorized according to their morphology. Preoperative MRI scans of the liver and abdominal follow-up imaging were assessed to determine whether the liver lesions found during staging CT appeared to be CRC metastases or not. RESULTS: In a consecutive cohort of 1232 patients with CRC who had undergone surgery, 84 patients with early-stage rectal cancer (cT1-2N0 on MRI) were identified. Of those 84 patients, 45 (54%) had 1 or more liver lesions on staging CT; a total of 122 liver lesions were observed, consisting of 95 indeterminate lesions (78%), 25 cysts (20%), and 2 hemangiomas (2%). Preoperative MRI of the liver and regular follow-up imaging revealed no synchronous or metachronous liver metastases in this cohort. CONCLUSIONS: In this study, small, hypoattenuating, indeterminate lesions of the liver were common in patients diagnosed with early rectal cancer and seemed to have no clinical significance. Additional preoperative imaging or follow-up imaging for indeterminate liver lesions in such patients may be unnecessary.


Sujet(s)
Tumeurs du foie , Tumeurs du rectum , Humains , Tumeurs du foie/imagerie diagnostique , Imagerie par résonance magnétique , Stadification tumorale , Tumeurs du rectum/imagerie diagnostique , Tumeurs du rectum/anatomopathologie , Tomodensitométrie
4.
Eur J Surg Oncol ; 47(11): 2749-2756, 2021 Nov.
Article de Anglais | MEDLINE | ID: mdl-34119380

RÉSUMÉ

INTRODUCTION: Indeterminate pulmonary nodules (IPNs) are frequently encountered on staging computed tomography (CT) in colorectal cancer (CRC) patients and they create diagnostic dilemmas. This systematic review and pooled analysis aims to estimate the incidence and risk of malignancy of IPNs and provide an overview of the existing literature on IPNs in CRC patients. MATERIALS AND METHODS: EMBASE, Pubmed and the Cochrane database were searched for papers published between January 2005 and April 2020. Studies describing the incidence of IPNs and the risk of malignancy in CRC patients and where the full text was available in the English language were considered for inclusion. Exclusion criteria included studies that used chest X-ray instead of CT, liver metastasis cohorts, studies with less than 60 CRC patients and reviews. RESULTS: A total of 18 studies met the inclusion criteria, involving 8637 patients. Pooled analysis revealed IPNs on staging chest CT in 1327 (15%) of the CRC patients. IPNs appeared to be metastatic disease during follow up in 16% of these patients. Regional lymph node metastases, liver metastases, location of the primary tumour in the rectum, larger IPN size and multiple IPNs are the five most frequently reported parameters predicting the risk of malignancy of IPNs. CONCLUSION: A risk stratification model for CRC patients with IPNs is warranted to enable an adequate selection of high risk patients for IPN follow up and to diminish the use of unnecessary repetitive chest CT-scans in the many low risk patients.


Sujet(s)
Tumeurs colorectales/anatomopathologie , Tumeurs du poumon/secondaire , Nodules pulmonaires multiples/secondaire , Humains , Tumeurs du poumon/imagerie diagnostique , Nodules pulmonaires multiples/imagerie diagnostique , Stadification tumorale , Tomodensitométrie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE